🧬 biology

MyD88 sustains a metastasis-competent cell state by promoting integrin-mediated adhesion in melanoma

This study identifies the adaptor protein MyD88 as a critical, environmentally responsive regulator that sustains melanoma metastatic competence by promoting integrin-mediated adhesion and plasticity, thereby enabling tumor cells to invade, intravasate, and colonize distant organs without affecting primary tumor growth.

Original authors: Federica Marocchi, Matteo Lafranconi, Federico Lazzarini, Fiorenza Lotti, Erika Mileti, Luca Mazzarella, Laura Furia, Angelica Zocchi, Giulia Bertolini, Gabriella Sozzi, Mario Faretta, Martin H. Schae

Published 2026-07-03

📖 5 min read🧠 Deep dive

CC BY 4.0

Original authors: Federica Marocchi, Matteo Lafranconi, Federico Lazzarini, Fiorenza Lotti, Erika Mileti, Luca Mazzarella, Laura Furia, Angelica Zocchi, Giulia Bertolini, Gabriella Sozzi, Mario Faretta, Martin H. Schaefer, Marine Melixetian, Luisa Lanfrancone

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ⚕️ This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer

The Big Picture: The "Escape Artist" Protein

Imagine a melanoma tumor as a crowded city. Most of the cells in this city are busy just building more buildings (growing the primary tumor). But a few special cells are "escape artists." They are the ones that pack their bags, leave the city, travel through the bloodstream, and start new colonies in distant organs like the lungs or liver. This process is called metastasis, and it is the main reason melanoma is so dangerous.

This paper asks a simple question: What makes these "escape artist" cells different from the regular cells?

The researchers discovered a specific protein inside the cancer cells called MyD88. Think of MyD88 as the master key or the GPS navigator for these escape artists. Without this key, the cells can still build the main city (the primary tumor grows just fine), but they completely lose the ability to leave and start new colonies elsewhere.

The Discovery: Finding the Key

To find this key, the researchers used a "genetic drop-out screen." Imagine they had a library of 77 different "keys" (genes) that might be important for escaping. They made copies of cancer cells where each copy had one specific key removed.

They injected these cells into mice and watched what happened.

The Result: When they removed the MyD88 key, the cancer cells stopped spreading to other organs. However, the main tumor in the skin kept growing normally.
The Conclusion: MyD88 isn't needed for the cancer to grow; it is strictly needed for the cancer to spread.

How It Works: The "Sticky" Strategy

So, how does MyD88 help the cancer spread? The paper explains that it acts like a super-sticky glue.

The Journey: To escape, a cancer cell must first stick to the walls of the blood vessels (the endothelium) and the surrounding scaffolding (the extracellular matrix).
The Glue: MyD88 turns on a program that produces "sticky" proteins called integrins. These act like grappling hooks or velcro.
The Mechanism: MyD88 talks to another protein called STAT3 (think of STAT3 as the foreman). MyD88 tells STAT3, "Turn on the glue factory!" STAT3 then orders the cell to produce more integrins.
The Result: With this extra glue, the cancer cells can:
- Climb out of the main tumor.
- Stick to blood vessel walls to get inside the bloodstream.
- Stick to the walls of distant organs to get out of the bloodstream and start a new tumor.

When the researchers removed MyD88, the cells became "slippery." They couldn't stick to anything, so they couldn't escape the main tumor or colonize new areas.

The Alarm System: Stress Makes the Key Stronger

The paper also found that MyD88 is very sensitive to the environment. It's like a survival alarm.

When the cancer cells face stress—such as:

Chemotherapy drugs (genotoxic stress),
Lack of oxygen or food (nutrient deprivation), or
Growth signals from the body,

...the cells sound the alarm. This alarm causes them to produce even more MyD88. This makes them stickier and more aggressive, helping them escape the stressful environment and find a new home.

The researchers showed that if you block the "glue factory" (STAT3) or the "sticky hooks" (integrins), the cancer cells lose their ability to invade, even if they are under stress.

The "Elite Squad" in the Tumor

Not every cell in the tumor has this key. The researchers found that within the main tumor, there is a small, special group of cells that naturally have high levels of MyD88.

These are the elite squad. They are the ones most likely to break out and become Circulating Tumor Cells (CTCs)—the cells floating in the blood.
When the researchers looked at the blood of the mice, they found that the cells floating there were almost exclusively the ones with high MyD88 levels.
If they removed MyD88 from the whole tumor, the number of these "escape artists" in the blood dropped dramatically, and the mice lived much longer because the cancer couldn't spread.

Summary in a Nutshell

The Problem: Melanoma spreads because some cells can detach and travel.
The Discovery: A protein called MyD88 is the engine that drives this spreading.
The Mechanism: MyD88 activates a "glue" system (integrins) via a foreman (STAT3), allowing cells to stick to surfaces and travel.
The Twist: MyD88 is not needed for the tumor to grow big, only for it to spread.
The Trigger: Stress (like chemo or low oxygen) turns up the volume on MyD88, making the cancer more dangerous.
The Proof: Removing MyD88 stops the spread without stopping the growth, and it drastically reduces the number of cancer cells found in the blood.

This research identifies MyD88 as a critical switch that turns a stationary tumor into a traveling one, specifically by helping cancer cells stick to their surroundings to make the journey.

Technical Summary: MyD88 Sustains a Metastasis-Competent Cell State by Promoting Integrin-Mediated Adhesion in Melanoma

Problem Statement
Metastatic dissemination is the primary cause of mortality in melanoma, yet the tumor cell-intrinsic mechanisms that integrate environmental cues to sustain metastatic competence remain incompletely understood. While non-genetic plasticity allows melanoma cells to transition between phenotypic states, it is unclear which specific regulators enable the acquisition of adhesion-dependent traits required for invasion and colonization of distant organs. Previous studies have linked Myeloid differentiation primary response 88 (MyD88) to tumorigenesis and primary tumor growth in specific contexts, but its role as a cell-autonomous regulator of spontaneous metastatic dissemination in melanoma has not been clearly defined.

Methodology
The authors employed a multi-faceted approach combining in vivo functional genomics, molecular biology, and single-cell analysis:

In Vivo Genetic Drop-out Screen: Using NRAS-mutant patient-derived xenograft (PDX) models (MM13 and MM16) in NSG mice, the authors performed a pooled shRNA screen targeting 77 candidate genes. Primary tumors were surgically resected at 300 mm³, and metastatic organs were collected to identify genes selectively required for dissemination but dispensable for primary tumor growth.
Functional Validation: MyD88 was silenced (shMyD88) or overexpressed (inducible Tet-On system) in multiple PDX models (MM13, MM16, MM23) and syngeneic murine models (SW1, B16-BL6). Phenotypes were assessed via metastatic burden quantification (lymph nodes, lungs, liver), survival analysis, and in vivo competition assays (tail vein injection of mixed shSCR/shMyD88 cells).
Mechanistic Assays: In vitro assays evaluated cell adhesion (fibronectin, endothelial monolayers), invasion (2D transwell, 3D spheroids in collagen), and transendothelial migration. Signaling pathways (STAT3, NF-κB) were interrogated using pharmacological inhibitors (BBI608 for STAT3, Resatorvid for TLR4) and Western blotting.
Environmental Stimuli: PDX cells were exposed to genotoxic stress (temozolomide), growth factors (TGF-β), and nutrient/oxygen deprivation to assess MyD88 induction and downstream plasticity.
Single-Cell and Spatial Analysis: Circulating Tumor Cells (CTCs) were isolated from PDX-bearing mice at different tumor stages and subjected to single-cell RNA sequencing (scRNA-seq) alongside matched primary tumors. Multiplexed immunofluorescence (MILAN workflow) was used to map MyD88 expression and adhesion markers within primary tumor sections.

Key Results

Identification of MyD88 as a Metastasis Driver: The drop-out screen identified MyD88 as a core dependency selectively required for metastatic progression. MyD88 silencing profoundly impaired metastatic dissemination to lymph nodes, lungs, and liver, significantly extending mouse survival, without affecting primary tumor growth kinetics or proliferation markers (Ki67).
Transcriptional Reprogramming: Bulk RNA-seq of shMyD88 tumors revealed a downregulation of genes associated with mesenchymal-like, invasive, and neural-crest-like states. The most significantly enriched pathway among downregulated genes was STAT3 signaling, while NF-κB activity remained unaffected.
Adhesion and Invasion Defects: MyD88 depletion reduced cell adhesion to fibronectin and endothelial cells (HMEC-1) and impaired transendothelial migration. Conversely, MyD88 overexpression enhanced invasion in 3D spheroids. These phenotypes were dependent on STAT3 signaling and integrin-mediated adhesion (specifically the $\alpha_V\beta_3$ integrin heterodimer), as evidenced by the rescue of phenotypes via STAT3 inhibition or cilengitide treatment.
Environmental Responsiveness: MyD88 expression was upregulated by environmental stressors (genotoxic stress, TGF-β, hypoxia/nutrient deprivation). These stimuli induced an invasive transcriptional program (including integrins and VEGF) that was attenuated in MyD88-silenced cells, suggesting MyD88 acts as a mediator translating environmental cues into metastatic competence.
MyD88 Identifies a Pro-Metastatic Subpopulation: Within primary tumors, a MyD88-high subpopulation exhibited increased expression of integrins (ITGAV, ITGB3) and adhesion markers. This subpopulation was enriched in cells that successfully transmigrated through endothelial barriers in vitro.
CTC Enrichment: scRNA-seq of isolated CTCs revealed a distinct, homogeneous transcriptional state (Cluster 7) characterized by high MyD88 expression, integrin signatures, and STAT3 activation. The proportion of MyD88-positive cells was approximately two-fold higher in CTCs compared to matched primary tumors, indicating that the MyD88-driven program is selectively enriched during the dissemination process.

Significance and Claims
The paper establishes MyD88 as a tumor cell-intrinsic regulator that links environmental responsiveness to the acquisition of adhesion-dependent metastatic traits. The authors claim that MyD88 is not merely a marker of inflammation but a functional driver that sustains a metastasis-competent cell state through a STAT3-dependent program. This program coordinates integrin-mediated interactions with the extracellular matrix and endothelium, facilitating critical steps of the metastatic cascade including local invasion, intravasation, and extravasation.

The study highlights that metastatic competence in melanoma is restricted to discrete, plastic subpopulations defined by MyD88 expression. By demonstrating that MyD88 is dispensable for primary tumor growth but essential for dissemination, the findings suggest that targeting the MyD88-STAT3 axis could specifically inhibit metastatic spread without affecting primary tumor burden. The work positions MyD88 as a key mediator that translates microenvironmental stress into a pro-adhesive, pro-metastatic phenotype, bridging the gap between environmental cues and the execution of the metastatic program.